| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of early onset and late recognition of Fabry disease with generalized lymphadenopathy, anorchidism, hypergonadotropic hypogonadism, and growth retardation
|
Sozin, S.E.
|
|
2007
|
|
S1 |
p. S27-S28
2 p.
|
artikel
|
| 2 |
A case of Fabry disease with multiple sclerosis
|
Bonometti, M.A.
|
|
2007
|
|
S1 |
p. S27-
1 p.
|
artikel
|
| 3 |
Addressing the needs of women with fabry disease
|
Wanner, Christoph
|
|
2009
|
|
S1 |
p. S9-
1 p.
|
artikel
|
| 4 |
Advances in the Diagnosis of Pompe Disease
|
Bodamer, Olaf
|
|
2008
|
|
S1 |
p. S2-
1 p.
|
artikel
|
| 5 |
Agalsidase beta treatment of patientswith Fabry disease for 54 months reduces globotriaosylceramide accumulation in multiple cell types of the kidney
|
Waldek, S.
|
|
2007
|
|
S1 |
p. S29-S30
2 p.
|
artikel
|
| 6 |
Alglucosidase Alfa (Myozyme®) in Infants and Children with Rapidly Progressive Pompe Disease
|
Corzo, Deyanira
|
|
2008
|
|
S1 |
p. S9-S10
2 p.
|
artikel
|
| 7 |
An overview of generalized anxiety disorder: disease state—appropriate therapy
|
Lydiard, R.Bruce
|
|
2000
|
|
S1 |
p. A3-A24
nvt p.
|
artikel
|
| 8 |
16. A report of the expert panel on cost-effectiveness in health and medicine (sponsored by the US public health service)
|
Kamlet, MarkScott
|
|
1996
|
|
S1 |
p. 11-
1 p.
|
artikel
|
| 9 |
Aripiprazole for the maintenance treatment of bipolar I disorder: A review
|
McIntyre, Roger S.
|
|
2010
|
|
S1 |
p. S32-S38
7 p.
|
artikel
|
| 10 |
Aripiprazole in schizophrenia and schizoaffective disorder: A review
|
Stip, Emmanuel
|
|
2010
|
|
S1 |
p. S3-S20
18 p.
|
artikel
|
| 11 |
Assessing antibodies to α-galactosidase A in fabry disease
|
Richards, Susan M.
|
|
2007
|
|
S1 |
p. S7-S8
2 p.
|
artikel
|
| 12 |
“Atypical variant” and an indirect diagnosis of fabry disease in a patient with end-stage renal disease
|
Ciabattini, F.
|
|
2007
|
|
S1 |
p. S26-S27
2 p.
|
artikel
|
| 13 |
Augmentation of standard depression therapy
|
Marangell, Lauren B.
|
|
2000
|
|
S1 |
p. A25-A41
nvt p.
|
artikel
|
| 14 |
Biomarkers for Pompe Disease
|
Maire, Irène
|
|
2008
|
|
S1 |
p. S4-S5
2 p.
|
artikel
|
| 15 |
Biomarkers in fabry disease
|
Auray-Blais, Christiane
|
|
2009
|
|
S1 |
p. S24-S25
2 p.
|
artikel
|
| 16 |
C9. A canadian pharmacoeconomic evaluation of zinecard
|
Williamson, T.
|
|
1996
|
|
S1 |
p. 24-25
2 p.
|
artikel
|
| 17 |
C3. A cost-density analysis of benign prostatic hyperplasia
|
Lanes, S.
|
|
1996
|
|
S1 |
p. 19-20
2 p.
|
artikel
|
| 18 |
C13. Application of medicare databases to a theoretical renal transplant markov model
|
Arnold, R.Goldberg
|
|
1996
|
|
S1 |
p. 28-
1 p.
|
artikel
|
| 19 |
Cardiac involvement in fabry disease:About numbers and notions
|
Strotmann, J.
|
|
2007
|
|
S1 |
p. S22-S23
2 p.
|
artikel
|
| 20 |
C27. A review of pharmacoeconomic studies in Japan
|
Ikeda, S.
|
|
1996
|
|
S1 |
p. 39-
1 p.
|
artikel
|
| 21 |
C5. Beyond acute care: the true cost of stroke
|
O'Brien, J.A.
|
|
1996
|
|
S1 |
p. 21-
1 p.
|
artikel
|
| 22 |
C11. Clinical and economic effects of Helicobacter pylori screening to prevent gastric cancer
|
Fendrick, A.M.
|
|
1996
|
|
S1 |
p. 26-
1 p.
|
artikel
|
| 23 |
C17. Combining multiple quality-of-life domains into aggregate outcome measures: a second-order factor approach
|
Lennox, R.
|
|
1996
|
|
S1 |
p. 31-
1 p.
|
artikel
|
| 24 |
C23. Comparative cost outcomes of inhaled corticosteroids for the treatment of asthma
|
Holzer, S.
|
|
1996
|
|
S1 |
p. 36-
1 p.
|
artikel
|
| 25 |
C28. Contribution of quasi-experimental research designs in pharmacoeconomic studies: empiric data from a case study of antiviral therapy
|
Itzler, R.F.
|
|
1996
|
|
S1 |
p. 40-
1 p.
|
artikel
|
| 26 |
C8. Cost-effectiveness of paclitaxel in advanced ovarian cancer
|
Riviere, M.
|
|
1996
|
|
S1 |
p. 24-
1 p.
|
artikel
|
| 27 |
C4. Cost-effectiveness trends of HMG-CoA reductase inhibitor therapy in a managed-care population
|
Petitta, A.
|
|
1996
|
|
S1 |
p. 20-21
2 p.
|
artikel
|
| 28 |
C26. Costs of human immunodeficiency virus+/acquired immunodeficiency syndrome at CD4+ counts using treatment protocols
|
Gable, C.
|
|
1996
|
|
S1 |
p. 38-39
2 p.
|
artikel
|
| 29 |
C6. Diagnosis of osteoporosis: use of a prescreen questionnaire
|
Lydick, E.
|
|
1996
|
|
S1 |
p. 22-
1 p.
|
artikel
|
| 30 |
C10. Economic evaluation of simvastatin in the secondary prevention of coronary heart disease in canada
|
Riviere, M.
|
|
1996
|
|
S1 |
p. 25-
1 p.
|
artikel
|
| 31 |
C16. Evaluating quality-of-life and health status instruments: development of scientific review criteria
|
Lohr, K.
|
|
1996
|
|
S1 |
p. 30-
1 p.
|
artikel
|
| 32 |
C22. Evaluation of community pharmacy-based anticoagulation clinics
|
Corey, R.
|
|
1996
|
|
S1 |
p. 35-
1 p.
|
artikel
|
| 33 |
C2. Guidelines for the use of claims databases for outcomes research
|
Motheral, B.R.
|
|
1996
|
|
S1 |
p. 19-
1 p.
|
artikel
|
| 34 |
Characterization of the somatosensorysensory profile of male patients with Fabry disease
|
Maag, R.
|
|
2007
|
|
S1 |
p. S25-
1 p.
|
artikel
|
| 35 |
Children and adolescents with fabry disease
|
Wijburg, Frits A.
|
|
2009
|
|
S1 |
p. S10-S11
2 p.
|
artikel
|
| 36 |
C7. Hip fractures in the United States: direct medical expenditures within subgroups
|
Martin, A.
|
|
1996
|
|
S1 |
p. 23-
1 p.
|
artikel
|
| 37 |
C25. International comparison of the cost of red cell transfusion: Canada and France
|
Souetre, E.
|
|
1996
|
|
S1 |
p. 38-
1 p.
|
artikel
|
| 38 |
C14. International economic evaluation of riluzole
|
Leclerc, C.
|
|
1996
|
|
S1 |
p. 29-
1 p.
|
artikel
|
| 39 |
C29. Latent variable models of health care utilization and costs for use in pharmacoeconomic research
|
Lennox, R.
|
|
1996
|
|
S1 |
p. 41-
1 p.
|
artikel
|
| 40 |
Clinical benefits of early treatment with Fabrazyme in Fabry disease
|
Waldek, S.
|
|
2007
|
|
S1 |
p. S29-
1 p.
|
artikel
|
| 41 |
Clinical characteristics of Hungarianpatients with fabry disease
|
Rákóczi, E.
|
|
2007
|
|
S1 |
p. S19-
1 p.
|
artikel
|
| 42 |
C12. Management and patients with past documented duodenal ulcer but unknown Helicobacter pylori status
|
Fendrick, A.M.
|
|
1996
|
|
S1 |
p. 27-
1 p.
|
artikel
|
| 43 |
CME Answer Sheet and Evaluation Form
|
|
|
2000
|
|
S1 |
p. A67-A68
nvt p.
|
artikel
|
| 44 |
CME Information
|
|
|
2000
|
|
S1 |
p. A63-
1 p.
|
artikel
|
| 45 |
CME Questions
|
|
|
2000
|
|
S1 |
p. A65-A66
nvt p.
|
artikel
|
| 46 |
C30. Methodologic issues in pharmacoeconomic evaluations of HMG-CoA reductase inhibitors used in the treatment of hyperlipidemia
|
Kong, S.X.
|
|
1996
|
|
S1 |
p. 41-42
2 p.
|
artikel
|
| 47 |
C19. Quality-adjusted life-years and healthy years equivalent: an empiric comparison
|
Wood, L.L.
|
|
1996
|
|
S1 |
p. 32-
1 p.
|
artikel
|
| 48 |
C18. Testing the constant proportional trade-off assumption using standard gamble
|
Bala, M.
|
|
1996
|
|
S1 |
p. 31-32
2 p.
|
artikel
|
| 49 |
C15. The economic impact of tacrine in the treatment of Alzheimer's disease
|
Henke, C.
|
|
1996
|
|
S1 |
p. 29-30
2 p.
|
artikel
|
| 50 |
C21. The impact of fears on quality of life in a silent disease (osteoporosis)
|
Lydick, E.
|
|
1996
|
|
S1 |
p. 34-
1 p.
|
artikel
|
| 51 |
C1. The use of technology assessment and disease management by managed-care pharmacy in the United States
|
Luce, B.R.
|
|
1996
|
|
S1 |
p. 18-
1 p.
|
artikel
|
| 52 |
C24. The utilization of a new nonsteroidal anti-inflammatory drug in a health maintenance organization
|
Rader, J.
|
|
1996
|
|
S1 |
p. 37-
1 p.
|
artikel
|
| 53 |
Current treatment trends in fabry disease
|
Linthorst, Gabor
|
|
2009
|
|
S1 |
p. S17-S18
2 p.
|
artikel
|
| 54 |
C20. Willingness to pay to avoid minor postanesthetic symptoms
|
Orkin, F.
|
|
1996
|
|
S1 |
p. 33-
1 p.
|
artikel
|
| 55 |
Deterioration of renal function in young adult patients with fabry disease and proteinuria
|
Bichet, D.G.
|
|
2007
|
|
S1 |
p. S33-
1 p.
|
artikel
|
| 56 |
Differential Diagnosis and Potential Misdiagnoses of Pompe Disease
|
Straub, Volker
|
|
2008
|
|
S1 |
p. S6-S7
2 p.
|
artikel
|
| 57 |
Disclosures
|
|
|
2000
|
|
S1 |
p. A62-
1 p.
|
artikel
|
| 58 |
Disclosures
|
|
|
2001
|
|
S1 |
p. A40-
1 p.
|
artikel
|
| 59 |
Diversity of calcium antagonists
|
Pitt, Bertram
|
|
1997
|
|
S1 |
p. 3-17
15 p.
|
artikel
|
| 60 |
Diversity of neuropathy in a familywith Fabry disease
|
Møller, A.T.
|
|
2007
|
|
S1 |
p. S24-S25
2 p.
|
artikel
|
| 61 |
Effects of enzyme replacement therapyin Fabry neuropathy
|
Politei, J.M.
|
|
2007
|
|
S1 |
p. S30-S31
2 p.
|
artikel
|
| 62 |
Effects of washout and dose-escalation periods on theefficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials
|
Rasmusen, Lee
|
|
2001
|
|
S1 |
p. A25-A30
nvt p.
|
artikel
|
| 63 |
Emerging therapeutic strategies for the treatment of fabry disease
|
Edmunds, Tim
|
|
2009
|
|
S1 |
p. S26-S27
2 p.
|
artikel
|
| 64 |
End-stage renal disease in fabry disease
|
Granata, A.
|
|
2007
|
|
S1 |
p. S20-
1 p.
|
artikel
|
| 65 |
Epilepsy: comprehensive care, quality of life, and factors preventing people with epilepsy from being employed
|
Yagi, Kazuichi
|
|
1998
|
|
S1 |
p. A19-A29
nvt p.
|
artikel
|
| 66 |
Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer
|
Robertson, John F.
|
|
2002
|
|
S1 |
p. A17-A30
nvt p.
|
artikel
|
| 67 |
Estrogen receptor downregulators: New options in endocrine therapy for advanced Breast cancer
|
O'Shaughnessy, Joyce
|
|
2002
|
|
S1 |
p. A43-A45
nvt p.
|
artikel
|
| 68 |
Estrogen receptor downregulators: New options in endocrine therapy for advanced breast cancer
|
O'Shaughnessy, Joyce
|
|
2002
|
|
S1 |
p. A41-A42
nvt p.
|
artikel
|
| 69 |
Estrogen receptor downregulators: New options in endocrine therapy for advanced breast cancer
|
O'Shaughnessy, Joyce
|
|
2002
|
|
S1 |
p. A47-A48
nvt p.
|
artikel
|
| 70 |
Evidence for selective low leukocyte enzyme activity levels associated with the G1170C>T 5'untranslated polymorphism of the α-galactosidase a gene
|
Ferreira, S.
|
|
2007
|
|
S1 |
p. S28-S29
2 p.
|
artikel
|
| 71 |
Expanding the use of anxiolytics in clinical practice
|
Rosenbaum, JerroldF.
|
|
2000
|
|
S1 |
p. A1-A2
nvt p.
|
artikel
|
| 72 |
Fabrazyme® therapy in pediatric patients with Fabry disease: Improvements in quality-of-life measures
|
Tylki-Szymanska, A.
|
|
2007
|
|
S1 |
p. S31-S32
2 p.
|
artikel
|
| 73 |
Fabry disease and bilateral renal cell carcinoma
|
Herrero, J.J.
|
|
2007
|
|
S1 |
p. S28-
1 p.
|
artikel
|
| 74 |
Fabry disease: classic phenotype in alarge family affected by a novel mutation (A292T) in the α-galactosidase a gene
|
Spanu, C.
|
|
2007
|
|
S1 |
p. S26-
1 p.
|
artikel
|
| 75 |
Fabry disease model: A rational approach to the management of fabry disease
|
Wanner, Christoph
|
|
2007
|
|
S1 |
p. S2-S5
4 p.
|
artikel
|
| 76 |
Fabry disease: The need to stratify patient populations to better understand the outcome of enzyme replacement therapy
|
Germain, Dominique P.
|
|
2007
|
|
S1 |
p. S17-S18
2 p.
|
artikel
|
| 77 |
Fabry disease: Worsening of hearingloss with enzyme replacement therapy
|
Moura, C.
|
|
2007
|
|
S1 |
p. S34-
1 p.
|
artikel
|
| 78 |
Foreword
|
Weidemann, Frank
|
|
2009
|
|
S1 |
p. S1-
1 p.
|
artikel
|
| 79 |
Foreword
|
McIntyre, Roger S.
|
|
2010
|
|
S1 |
p. S1-S2
2 p.
|
artikel
|
| 80 |
Foreword
|
Desnuelle, Claude
|
|
2008
|
|
S1 |
p. S1-
1 p.
|
artikel
|
| 81 |
Foreword
|
Wanner, Christoph
|
|
2007
|
|
S1 |
p. S1-
1 p.
|
artikel
|
| 82 |
Frequency of 5'untranslated region single nucleotide polymorphisms of the α-galactosidase a gene in the Portuguese population
|
Ferreira, S.
|
|
2007
|
|
S1 |
p. S28-
1 p.
|
artikel
|
| 83 |
Fulvestrant: Clinical application of an estrogen receptor downregulator
|
Torosian, Michael
|
|
2002
|
|
S1 |
p. A31-A40
nvt p.
|
artikel
|
| 84 |
Genetic mechanisms of psychosis: In vivo and postmortem genomics
|
Weinberger, Daniel R.
|
|
2005
|
|
S1 |
p. S8-S15
8 p.
|
artikel
|
| 85 |
Genomic approaches to schizophrenia
|
Owen, Michael J.
|
|
2005
|
|
S1 |
p. S2-S7
6 p.
|
artikel
|
| 86 |
Historical perspective on hormonal therapy of advanced breast cancer
|
Jordan, Craig
|
|
2002
|
|
S1 |
p. A3-A16
nvt p.
|
artikel
|
| 87 |
Hypertension and pathologic cardiovascular remodeling: a potential therapeutic role for T-type calcium antagonists
|
Giles, Thomas D.
|
|
1997
|
|
S1 |
p. 27-38
12 p.
|
artikel
|
| 88 |
I13. Advances in statistical considerations in prospective pharmacoeconomic studies
|
Bigelow, RobertH.
|
|
1996
|
|
S1 |
p. 17-
1 p.
|
artikel
|
| 89 |
I11. Applications of large databases to evaluate cost-effective therapy
|
Goldberg Arnold, RenéeJ.
|
|
1996
|
|
S1 |
p. 15-16
2 p.
|
artikel
|
| 90 |
I5. Draft association for pharmacoeconomics and outcomes research consensus guidance for economic evaluation of pharmaceutical therapy: the health care provider's perspective
|
Finder, Steven
|
|
1996
|
|
S1 |
p. 10-
1 p.
|
artikel
|
| 91 |
I2. Guidelines for economic evaluation of pharmaceuticals: Australia—an evolutionary process
|
Mitchell, AndrewS.
|
|
1996
|
|
S1 |
p. 7-8
2 p.
|
artikel
|
| 92 |
I1. Guidelines for economic evaluation of pharmaceuticals: Canada's practical experiences
|
Otten, Nicolaas
|
|
1996
|
|
S1 |
p. 6-7
2 p.
|
artikel
|
| 93 |
I10. Integration of inpatient and outpatient services: utilizing pharmacoeconomic and outcomes research to guide the way
|
Just, PaulM.
|
|
1996
|
|
S1 |
p. 14-
1 p.
|
artikel
|
| 94 |
Immunophenotyping of glomerular cellsin renal biopsies provides evidence of selective podocyte involvement in Fabry disease
|
Franeta, A.-J.
|
|
2007
|
|
S1 |
p. S21-
1 p.
|
artikel
|
| 95 |
Impact of treatment with agalsidasebeta on health-related quality of life in patients with Fabry disease
|
Badia, X.
|
|
2007
|
|
S1 |
p. S31-
1 p.
|
artikel
|
| 96 |
Improving compliance and quality of life with home infusions for the treatment of fabry disease
|
Cousins, Alison J.
|
|
2009
|
|
S1 |
p. S12-S13
2 p.
|
artikel
|
| 97 |
Insights into the Pathophysiology of Pompe Disease
|
Thurberg, Beth
|
|
2008
|
|
S1 |
p. S3-
1 p.
|
artikel
|
| 98 |
Intermitent long-term treatment in a patient with Fabry disease
|
Del Pozo, C.
|
|
2007
|
|
S1 |
p. S32-
1 p.
|
artikel
|
| 99 |
Introduction
|
O'Shaughnessy, Joyce
|
|
2002
|
|
S1 |
p. A1-A2
nvt p.
|
artikel
|
| 100 |
Introduction
|
Abi-Dargham, Anissa
|
|
2005
|
|
S1 |
p. S1-
1 p.
|
artikel
|
| 101 |
I3. Pharmacoeconomic evaluations: a pharmaceutical company's perspective
|
Garrison Jr., LouisP.
|
|
1996
|
|
S1 |
p. 8-9
2 p.
|
artikel
|
| 102 |
I4. Regulating pharmacoeconomic information: prospects for public and private review in the United States
|
Neumann, PeterJ.
|
|
1996
|
|
S1 |
p. 9-
1 p.
|
artikel
|
| 103 |
I12. Statistical considerations in cost-effectiveness evaluations
|
Heyse, JosephF.
|
|
1996
|
|
S1 |
p. 16-
1 p.
|
artikel
|
| 104 |
I9. Using pharmacoeconomic research in hospital formulary decisions
|
Gibson, GeneA.
|
|
1996
|
|
S1 |
p. 13-
1 p.
|
artikel
|
| 105 |
17. Just the FACCTS—the consumers' perspective on outcomes accountability
|
McNeill, Dwight
|
|
1996
|
|
S1 |
p. 11-
1 p.
|
artikel
|
| 106 |
Long-term agalsidase beta therapy is associated with improvements in pain and quality of life among patients with Fabry disease
|
Guffon, N.
|
|
2007
|
|
S1 |
p. S31-
1 p.
|
artikel
|
| 107 |
Mechanism of action of antipsychotic drugs: From dopamine D2 receptor antagonism to glutamate NMDA facilitation
|
Laruelle, Marc
|
|
2005
|
|
S1 |
p. S16-S24
9 p.
|
artikel
|
| 108 |
Multisystemic cardiac involvement: Beyond left ventricular hypertrophy
|
Zamorano, J.L.
|
|
2007
|
|
S1 |
p. S19-
1 p.
|
artikel
|
| 109 |
Mutations in exon 7 of the α-galactosidase a gene
|
Rosenberg, K.
|
|
2007
|
|
S1 |
p. S34-
1 p.
|
artikel
|
| 110 |
Natural Course and Effects of Enzyme Therapy in Adults with Pompe Disease
|
Ploeg, Ans van der
|
|
2008
|
|
S1 |
p. S15-S16
2 p.
|
artikel
|
| 111 |
New directions in the treatment of antidepressant-induced sexual dysfunction
|
Rothschild, Anthony J.
|
|
2000
|
|
S1 |
p. A42-A61
nvt p.
|
artikel
|
| 112 |
Nutritional Recommendations for Patients with Glycogen Storage Disease Type II
|
Angelini, Corrado
|
|
2008
|
|
S1 |
p. S21-
1 p.
|
artikel
|
| 113 |
Optimizing treatment to reach therapeutic goals in fabry disease
|
Warnock, David G.
|
|
2009
|
|
S1 |
p. S15-S16
2 p.
|
artikel
|
| 114 |
Overview
|
Morris, John C.
|
|
2001
|
|
S1 |
p. A1-A2
nvt p.
|
artikel
|
| 115 |
P23. A comparison of the current status of pharmacoeconomic research in Japan and the United States
|
Watrous, M.L.
|
|
1996
|
|
S1 |
p. 58-59
2 p.
|
artikel
|
| 116 |
P19. Affectivity and affects balance as highly sensitive measures of psychological outcome and well-being in trials with medical and psychiatric populations
|
Derogatis, L.R.
|
|
1996
|
|
S1 |
p. 56-
1 p.
|
artikel
|
| 117 |
P27. A global renal outcomes study using unique data collection and analysis tools
|
Chahal, A.
|
|
1996
|
|
S1 |
p. 61-62
2 p.
|
artikel
|
| 118 |
Panel discussion:recommendations for prescribers
|
Morris, John C.
|
|
2001
|
|
S1 |
p. A31-A39
nvt p.
|
artikel
|
| 119 |
P8. A payer perspective cost-benefit analysis of felbamate in a managed-care setting
|
Klein, E.G.
|
|
1996
|
|
S1 |
p. 48-49
2 p.
|
artikel
|
| 120 |
Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis
|
Moisan, Jocelyne
|
|
2010
|
|
S1 |
p. S21-S31
11 p.
|
artikel
|
| 121 |
P17. Comparison of family costs of two childhood illnesses—varicella and otitis media
|
Lydick, E.
|
|
1996
|
|
S1 |
p. 54-55
2 p.
|
artikel
|
| 122 |
P2. Compromising optimal ambulatory resource utilization: evidence from health services prescribing associated with pharmaceutical products
|
Duttagupta, S.
|
|
1996
|
|
S1 |
p. 44-
1 p.
|
artikel
|
| 123 |
P4. Cost demographics of prescribing patterns
|
Nunlee, M.
|
|
1996
|
|
S1 |
p. 45-46
2 p.
|
artikel
|
| 124 |
P24. Cost-prevention analysis: a new term for a familiar analysis
|
Copley-Merriman, C.
|
|
1996
|
|
S1 |
p. 59-
1 p.
|
artikel
|
| 125 |
P12. Costs of prescription drugs for diabetes mellitus medicaid patients in Alabama: a population-based study
|
Guo, J.J.
|
|
1996
|
|
S1 |
p. 51-
1 p.
|
artikel
|
| 126 |
P10. Economic evaluation of drug utilization review on medicaid pharmacy dispensing behavior: an empiric marginal analysis
|
Guo, J.J.
|
|
1996
|
|
S1 |
p. 50-
1 p.
|
artikel
|
| 127 |
Pediatrics: implementing the promise of early intervention for fabry disease
|
Raas-Rothschild, Annick
|
|
2007
|
|
S1 |
p. S6-
1 p.
|
artikel
|
| 128 |
P11. Effects of drug utilization review on medicaid prescriber behavior: a latent means modeling analysis
|
Guo, J.J.
|
|
1996
|
|
S1 |
p. 50-51
2 p.
|
artikel
|
| 129 |
Peripheral nervous system involvement in fabry disease: Role in morbidity and mortality
|
Hilz, Max J.
|
|
2007
|
|
S1 |
p. S11-S12
2 p.
|
artikel
|
| 130 |
P18. Evaluating red blood cell transfusions using a large clinical database
|
Ollendorf, D.
|
|
1996
|
|
S1 |
p. 55-
1 p.
|
artikel
|
| 131 |
Pharmacoeconomics and outcomes research—visions for the 21st century
|
McGhan, WilliamF.
|
|
1996
|
|
S1 |
p. 1-4
4 p.
|
artikel
|
| 132 |
Pharmacokinetic profiles of current therapiesfor Alzheimer's disease: implications for switching to galantamine
|
Farlow, Martin R.
|
|
2001
|
|
S1 |
p. A13-A24
nvt p.
|
artikel
|
| 133 |
Pharmacokinetic rationale for switching from donepezil to galantamine
|
Maelicke, Alfred
|
|
2001
|
|
S1 |
p. A8-A12
nvt p.
|
artikel
|
| 134 |
Physical capacity and perception ofexertion in 72 patients with fabry disease
|
Breunig, F.B.
|
|
2007
|
|
S1 |
p. S24-
1 p.
|
artikel
|
| 135 |
Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists
|
Hermsmeyer, Kent
|
|
1997
|
|
S1 |
p. 18-26
9 p.
|
artikel
|
| 136 |
P32. Influence of infection on length of hospital stay, mortality, and postdischarge level of care after surgical procedures
|
Bakst, A.W.
|
|
1996
|
|
S1 |
p. 65-
1 p.
|
artikel
|
| 137 |
P1. Information management technologies in outcomes research
|
Khan, Z.M.
|
|
1996
|
|
S1 |
p. 43-
1 p.
|
artikel
|
| 138 |
P16. Ketorolac does not preemptively reduce postoperative pain following laparoscopic tubal surgery
|
Lee, V.C.
|
|
1996
|
|
S1 |
p. 53-54
2 p.
|
artikel
|
| 139 |
P26. Mobile computing with personal digital assistants in a clinical setting
|
Freedman, N.
|
|
1996
|
|
S1 |
p. 60-61
2 p.
|
artikel
|
| 140 |
Pompe Disease in Adults-Advanced Stage
|
Annane, Djillali
|
|
2008
|
|
S1 |
p. S13-S14
2 p.
|
artikel
|
| 141 |
Pompe Disease in Children-Early to Mid-stage
|
Capelle, Carine van
|
|
2008
|
|
S1 |
p. S11-S12
2 p.
|
artikel
|
| 142 |
Pompe Disease: Neurology Perspectives
|
Müller-Felber, Wolfgang
|
|
2008
|
|
S1 |
p. S17-S18
2 p.
|
artikel
|
| 143 |
Pompe Disease: Pulmonology Perspectives
|
Annane, Djillali
|
|
2008
|
|
S1 |
p. S19-S20
2 p.
|
artikel
|
| 144 |
PORTYSTROKE: Screening genetic conditions in portuguese young stroke patients
|
Viana-Baptista, Miguel
|
|
2009
|
|
S1 |
p. S3-S4
2 p.
|
artikel
|
| 145 |
Poster abstracts
|
|
|
2009
|
|
S1 |
p. S29-S45
17 p.
|
artikel
|
| 146 |
Poster Abstracts
|
|
|
2008
|
|
S1 |
p. S25-S37
13 p.
|
artikel
|
| 147 |
P20. Patient electronic medical record—applications for a new age of treatment data
|
Copeland, K.
|
|
1996
|
|
S1 |
p. 56-57
2 p.
|
artikel
|
| 148 |
P9. Patient outcomes: documentation of cost savings and cost avoidance
|
Mutnick, A.
|
|
1996
|
|
S1 |
p. 49-
1 p.
|
artikel
|
| 149 |
P21. Pharmacoeconomic analysis in the formulary decision-making process
|
Duong, P.
|
|
1996
|
|
S1 |
p. 57-
1 p.
|
artikel
|
| 150 |
P31. Pharmacoeconomic evaluation of oral therapies for onychomycosis: a US model
|
Marchetti, A.
|
|
1996
|
|
S1 |
p. 64-65
2 p.
|
artikel
|
| 151 |
P13. Power calculations for peptic disease utilization and expenditure studies
|
Cleary, M.
|
|
1996
|
|
S1 |
p. 52-
1 p.
|
artikel
|
| 152 |
P6. Practical issues in conducting pharmacoeconomic studies
|
Rajagopalan, R.
|
|
1996
|
|
S1 |
p. 47-
1 p.
|
artikel
|
| 153 |
P5. Present situation of pharmacoeconomic evaluation by Japanese pharmaceutical companies
|
Inoue, S.
|
|
1996
|
|
S1 |
p. 46-
1 p.
|
artikel
|
| 154 |
P14. Prevalence rates of antidepressant treatment by sex, age, and health plan
|
Garrard, J.
|
|
1996
|
|
S1 |
p. 52-
1 p.
|
artikel
|
| 155 |
P25. PRISM: delivering the pharmacoeconomic message
|
Caro, J.J.
|
|
1996
|
|
S1 |
p. 60-
1 p.
|
artikel
|
| 156 |
P22. Quinolone selection in a for-profit hospital: a model for pharmacoeconomics
|
Williams, T.L.
|
|
1996
|
|
S1 |
p. 58-
1 p.
|
artikel
|
| 157 |
P15. Rate of esophageal dilations after the introduction of omeprazole
|
Cleary, M.
|
|
1996
|
|
S1 |
p. 53-
1 p.
|
artikel
|
| 158 |
Pregnancy and quality of life in women with epilepsy
|
Kaneko, Sunao
|
|
1998
|
|
S1 |
p. A30-A47
nvt p.
|
artikel
|
| 159 |
Prevalence of fabry disease in a cohortof 479 unrelated patients with hypertrophic cardiomyopathy
|
Monserrat, L.
|
|
2007
|
|
S1 |
p. S23-S24
2 p.
|
artikel
|
| 160 |
Prevalence of fabry disease in malepatients with chronic renal disease not receiving renal replacement therapy: Preliminary report of a multicenter study
|
Herrero, J.A.
|
|
2007
|
|
S1 |
p. S21-
1 p.
|
artikel
|
| 161 |
Progression of fabry cardiomyopathy
|
Strotmann, Jörg
|
|
2007
|
|
S1 |
p. S13-S14
2 p.
|
artikel
|
| 162 |
Progression of left ventricularhypertrophy in fabry disease is faster in patients with phosphocreatine depletion: A phosphorus-31 magnetic resonance spectroscopy study
|
Bultas, J.
|
|
2007
|
|
S1 |
p. S24-
1 p.
|
artikel
|
| 163 |
Progressive development of microalbuminuria and proteinuria in males and females with fabry disease
|
Ortiz, A.
|
|
2007
|
|
S1 |
p. S19-S20
2 p.
|
artikel
|
| 164 |
Proteinuria signals the risk of diseaseprogression as strongly in female as in male patients with fabry disease
|
Waldek, S.
|
|
2007
|
|
S1 |
p. S20-
1 p.
|
artikel
|
| 165 |
18. Providing cost-effective therapy using pharmacoeconomic evaluations: the US public sector approach
|
Finder, Steven
|
|
1996
|
|
S1 |
p. 12-
1 p.
|
artikel
|
| 166 |
P33. Staged diabetes management: a complete disease state management
|
Ginsberg, B.H.
|
|
1996
|
|
S1 |
p. 66-
1 p.
|
artikel
|
| 167 |
P7. Suboptimal prescribing and related outcomes in the nursing home medicaid elderly
|
Gupta, S.
|
|
1996
|
|
S1 |
p. 47-48
2 p.
|
artikel
|
| 168 |
Psychosocial aspects of fabry disease and their impact on optimal disease management
|
Mehta, Atul B.
|
|
2009
|
|
S1 |
p. S7-S8
2 p.
|
artikel
|
| 169 |
P3. The impact of physician and parent conformance with practice parameters on outcomes of pediatric gastroenteritis
|
Merrick, N.
|
|
1996
|
|
S1 |
p. 45-
1 p.
|
artikel
|
| 170 |
P28. The use of markov models in the pharmacoeconomic evaluation of relapsing/remitting diseases
|
Hagan, M.
|
|
1996
|
|
S1 |
p. 62-
1 p.
|
artikel
|
| 171 |
P30. The value of pharmacoeconomics in medicare/medicaid programs
|
Goppold, B.
|
|
1996
|
|
S1 |
p. 64-
1 p.
|
artikel
|
| 172 |
Pursuing the diagnosis of fabry disease in at-risk family members
|
Reyes-Rosano, Miguel Angel
|
|
2009
|
|
S1 |
p. S5-S6
2 p.
|
artikel
|
| 173 |
P29. Use and influence of pharmacoeconomics in decision making in hospitals
|
Gore, M.
|
|
1996
|
|
S1 |
p. 63-
1 p.
|
artikel
|
| 174 |
Quality of life and epilepsy: the liverpool experience
|
Baker, Gus A.
|
|
1998
|
|
S1 |
p. A2-A12
nvt p.
|
artikel
|
| 175 |
Quality of life in epilepsy
|
Yagi, Kazuichi
|
|
1998
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 176 |
Quality of life of people with epilepsy in the United States
|
Leppik, Ilo E.
|
|
1998
|
|
S1 |
p. A13-A18
nvt p.
|
artikel
|
| 177 |
Quality of life research in adults with epilepsy in Japan
|
Kugoh, Toshiaki
|
|
1998
|
|
S1 |
p. A48-A57
nvt p.
|
artikel
|
| 178 |
Rationale for the use of calcium antagonists in the treatment of silent myocardial ischemia
|
Cohn, Peter F.
|
|
1997
|
|
S1 |
p. 74-91
18 p.
|
artikel
|
| 179 |
Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality
|
Habib, Gabriel
|
|
1997
|
|
S1 |
p. 39-52
14 p.
|
artikel
|
| 180 |
Recent identification of a fabry kindred in rural Newfoundland, Canada
|
Murphy, S.
|
|
2007
|
|
S1 |
p. S25-
1 p.
|
artikel
|
| 181 |
Relationship between cardiac and kidneyinvolvement in fabry patients presenting with a classic phenotype
|
Strotmann, J.
|
|
2007
|
|
S1 |
p. S22-
1 p.
|
artikel
|
| 182 |
Relationship between chronic renal disease, blood pressure, and left ventricular hypertrophy in males and females with Fabry disease
|
Ortiz, A.
|
|
2007
|
|
S1 |
p. S21-S22
2 p.
|
artikel
|
| 183 |
Right ventricular involvement in Fabry disease
|
Dostalova, G.
|
|
2007
|
|
S1 |
p. S23-
1 p.
|
artikel
|
| 184 |
Roundtable discussion
|
|
|
1998
|
|
S1 |
p. A58-A60
nvt p.
|
artikel
|
| 185 |
Safety of calcium antagonists in patients with congestive heart failure
|
Katz, Stuart
|
|
1997
|
|
S1 |
p. 92-113
22 p.
|
artikel
|
| 186 |
Screening of Newborns for Pompe Disease and/or Other Lysosomal Storage Disorders
|
Bodamer, Olaf
|
|
2008
|
|
S1 |
p. S8-
1 p.
|
artikel
|
| 187 |
Searching for patients with fabry disease in clinical practice
|
Waldek, Stephen
|
|
2009
|
|
S1 |
p. S2-
1 p.
|
artikel
|
| 188 |
Staging fabry disease
|
Weidemann, Frank
|
|
2009
|
|
S1 |
p. S14-
1 p.
|
artikel
|
| 189 |
Staging of fabry disease using renal biopsies
|
Oliveira, João Paulo
|
|
2007
|
|
S1 |
p. S15-S16
2 p.
|
artikel
|
| 190 |
Stroke and brain structural alterations in fabry disease
|
Fellgiebel, Andreas
|
|
2007
|
|
S1 |
p. S9-S10
2 p.
|
artikel
|
| 191 |
Switching previous therapies for Alzheimer's disease to galantamine
|
Ferris, Steven H.
|
|
2001
|
|
S1 |
p. A3-A7
nvt p.
|
artikel
|
| 192 |
The clinical significance of neurohormonal activation
|
Pool, Peter E.
|
|
1997
|
|
S1 |
p. 53-73
21 p.
|
artikel
|
| 193 |
The expanding role of calcium antagonists in cardiovascular disease
|
Oparil, Suzanne
|
|
1997
|
|
S1 |
p. 1-2
2 p.
|
artikel
|
| 194 |
The fabry registry: Looking at tomorrow
|
Sims, Katherine B.
|
|
2009
|
|
S1 |
p. S22-S23
2 p.
|
artikel
|
| 195 |
The future of pharmacoeconomics: bridging science and practice
|
Drummond, Michael
|
|
1996
|
|
S1 |
p. 5-
1 p.
|
artikel
|
| 196 |
The long-term effect of enzyme replacement therapy on regression of left ventricular hypertrophy in patients with Fabry cardiomyopathy. Impact of baseline findings
|
Strotmann, J.
|
|
2007
|
|
S1 |
p. S30-
1 p.
|
artikel
|
| 197 |
The Pompe Registry: Centralized Data Collection to Track the Natural Course of Pompe Disease
|
Merlini, Luciano
|
|
2008
|
|
S1 |
p. S24-
1 p.
|
artikel
|
| 198 |
The Role of Physiotherapy and Exercise in the Management of Patients with Pompe Disease
|
Roberts, Mark
|
|
2008
|
|
S1 |
p. S22-S23
2 p.
|
artikel
|
| 199 |
Treatment of children and pregnant women with fabry disease
|
Ramaswami, Uma
|
|
2009
|
|
S1 |
p. S19-S21
3 p.
|
artikel
|
| 200 |
Treatment of cognitive dysfunction in schizophrenia
|
Peuskens, Joseph
|
|
2005
|
|
S1 |
p. S25-S37
13 p.
|
artikel
|
| 201 |
Unsuspected diagnosis of fabry disease in an 81-year-old male with microscopic polyangiitis
|
Aaron, L.
|
|
2007
|
|
S1 |
p. S26-
1 p.
|
artikel
|
| 202 |
Where are the deposits in cornea verticillata in fabry disease?
|
Lanzl, I.
|
|
2007
|
|
S1 |
p. S25-
1 p.
|
artikel
|
| 203 |
Withdrawal of enzyme replacement therapy in Fabry disease: Indirect evidence of treatment benefit?
|
West, M.
|
|
2007
|
|
S1 |
p. S32-S33
2 p.
|
artikel
|
Tijdschrift beschrijving